

**TABLE III. SSRI Clinical Trials Outcomes**

**Table III. SSRI Clinical Trials Outcomes**

	<b>Trials</b>	<b>Sample size</b>		<b>Effect size (95% CI)</b>	<b>Outcome</b>
		<b>treatment</b>	<b>placebo</b>		
Fluoxetine	Tads (2004)	109	112	60.6% response (51-70%)	Superior to placebo (12 weeks)
	Emslie (2002)	109	110	RR 0.67 (0.52-0.87)	Superior to placebo (7-8 weeks)
	Emslie (1997)	48	48	RR 0.78 (0.67-0.90)	Superior to placebo (7-8 weeks)
Sertraline	Wagner (2003)	189	187	RR 0.80 (0.63-1.00)	Marginal improvement (10 weeks)
	Unpublished	97	91	Random effects	
	Unpublished	92	96	RR 0.92 (0.62-1.38)	
Paroxetine	Keller (2001)	93	87	RR 0.79 (0.55-1.13)	Not better than placebo (8 weeks)
	Unpublished	177	91	RR 0.95 (0.70-1.28)	Not better than placebo (8-12 weeks)
	Unpublished	182	93		Limited efficacy data
Citalopram	Unpublished	89	85		Limited efficacy data
	Unpublished	121	112		Limited efficacy data
Venlafaxine	Mandoki (1997)	40		SMD 0.25 (-0.44 to 0.93)	Not better than placebo (6 weeks)
	Unpublished (2)	182	179	SMD -0.29 (-0.51 to -0.07)	Not better than placebo (8 weeks)

CI, confidence interval; RR, relative risk; SAE, serious adverse event; SI, suicidal ideation; SMD, standardized mean difference;

\*Unpublished data summarized in Whittington et al. (2004) and obtained from Committee on Safety of Medicines Report: Selective Serotonin reuptake inhibitors (SSRIs): Overview of regulatory status and CSM advice relating to major depressive disorder (MDD) in children and adolescents including a summary of available safety and efficacy data. (12/10/03).